{"id":"W3080424252","doi":"10.1136/esmoopen-2020-000714","title":"Second-line cabozantinib after sorafenib treatment for advanced hepatocellular carcinoma: a subgroup analysis of the phase 3 CELESTIAL trial","year":2020,"lang":"en","type":"article","venue":"ESMO Open","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Cancer Research UK; Exelixis","keywords":"Sorafenib; Cabozantinib; Medicine; Placebo; Hepatocellular carcinoma; Internal medicine; Clinical endpoint; Subgroup analysis; Population; Oncology; Gastroenterology; Randomized controlled trial; Surgery; Confidence interval; Cancer; Pathology","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002063525,0.0003548671,0.00117502,0.00009998066,0.0001217737,0.00005172817,0.0003592294,0.0001341244,0.001325668],"category_scores_gemma":[0.00008158619,0.0002336477,0.0010151,0.0008677774,0.00008414564,0.000126747,0.0001596702,0.0001166044,0.00001429999],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008490078,"about_ca_system_score_gemma":0.0003031156,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004649005,"about_ca_topic_score_gemma":0.0003362565,"domain_scores_codex":[0.9980029,0.000126406,0.0006326421,0.0005970626,0.000275388,0.0003655924],"domain_scores_gemma":[0.9985774,0.0001225361,0.0002603188,0.0006258692,0.0001375006,0.0002763865],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1647628,0.00307052,0.8110527,0.0001732776,0.00494348,0.0003679446,0.002466581,0.000009241274,0.005622688,0.0001058478,0.0004256289,0.006999331],"study_design_scores_gemma":[0.4860751,0.02044323,0.04007214,0.00008860758,0.0299062,0.00001342228,0.0002983696,0.04840893,0.3074965,0.0000376859,0.06627652,0.0008833124],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9899057,0.0003336004,0.0002299498,0.001685341,0.000168257,0.006662827,0.0005599596,0.00003067593,0.0004237508],"genre_scores_gemma":[0.9954584,0.00001588236,0.0008134579,0.0004639267,0.0002739936,0.00137632,0.0006433483,0.00004837589,0.0009063557],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7709805,"threshold_uncertainty_score":0.9995872,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1231581948242682,"score_gpt":0.3314540554563082,"score_spread":0.20829586063204,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}